Background: We conducted a large international study to estimate fractions of head and neck cancers (HNCs) attributable to human papillomavirus (HPV-AFs) using six HPV-related biomarkers of viral detection, transcription, and cellular transformation.
Strong evidence has accumulated in the last 15 years showing that certain human papillomaviruses (HPVs) are etiologically involved in a subset of head and neck cancers (HNCs) (1) . While virtually all cervical cancers are considered HPV driven (2) , the quantitative assessment of the etiological involvement of HPVs in HNCs is challenged by its multifactorial etiology largely attributed to tobacco and alcohol use (3) (4) (5) . Consequently, the unequivocal fraction of HPV-DNA-positive HNCs for which HPV infection is indeed the truly triggering carcinogenic event is unknown, and its estimation remains a challenge (6) . Further, the presence of HPV-DNA in HNCs is not sufficient to prove viral causation as it might just reflect a transient infection unrelated to the carcinogenic process (7, 8) . It is thus crucial to explore the individual and combined expression patterns of other markers associated with HPV-induced carcinogenesis to assess the biological and oncogenic activities of HPVs identified in these cancers.
To that end, we conducted a large international study in HNCs to assess levels of six markers associated with HPV carcinogenesis using a strict single protocol to standardize the entire process that spans from sample selection and processing to pathology review and testing. The ultimate goal of the study was to generate robust estimates of the HPV-attributable fractions (AFs) in HNCs by anatomical site, sex, and geography.
Methods

Study Design
We carried out an international, cross-sectional study to assess the prevalence of viral DNA and other markers of HPV-related carcinogenesis in formalin-fixed, paraffin-embedded (FFPE) samples of HNCs. Protocols were approved by the ethics committee of the Catalan Institute of Oncology-ICO (Comitè Ètic d'Investigació Clínica de l'Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain), which required no informed consent to use archived tumor samples.
Selection of Samples
HNC samples were selected from an international network of pathology departments identified in 44 centers from 29 countries in Europe, Africa, Asia, and America. Participating centers were requested to provide samples using a common protocol for sample selection, retrieval, processing, and shipping to ICO. Selected cancer patients had to fulfill pre-established inclusion criteria: to be diagnosed with primary invasive cancer of the oral cavity (OC), pharynx, or larynx under specific codes of the International Classification of Diseases version 10 (ICD-10); to have complete article data on year of diagnosis and site of the tumor; and to be selected in a consecutive or random manner from 1990 onwards. Centers were asked to contribute if possible a minimum of 50 samples per major anatomic HNC site. In order to assess potential carryover contamination at the local level, we additionally requested tissue samples of patients with non-HPV related diagnoses processed in the same laboratory and close to the patients' diagnosis time. Cancers of the salivary glands, nasopharynx, and external lip were initially not requested because they are a priori not considered to be related to HPVs. Nevertheless, we included a series of nasopharyngeal cancers from Europe (n = 37), America (n = 8), Africa (n = 35), and Asia (n = 21).
Based on previously published site-specific estimates of HPV-DNA prevalence (9) , optimal sample size was set at around 1000 patients per major cancer site in order to obtain HPV-DNA prevalence estimates with a ±2.5% precision.
FFPE Blocks Processing and Histopathological Evaluation
FFPE blocks were re-embedded at ICO whenever necessary. At least four paraffin sections were obtained for each block. First and last sections were used for histopathological evaluation, and the in-between ones for HPV testing (sandwich method). Additional slides were obtained to assess expression of cellular proteins by immunohistochemistry (IHC). FFPE blocks were processed under strict pre/post polymerase chain reaction (PCR) physical separation, and blank paraffin blocks were systematically tested in parallel to serve as sentinels for contamination as previously published (10) . Pathology review was performed blind with respect to the original local diagnosis and followed a pre-established algorithm for diagnostic consensus involving four pathologists. First, all pathology slides were reviewed by a trained pathologist at ICO. Cancers regarded as difficult to classify (n = 668) were further reviewed by two senior expert pathologists also at ICO. Finally, samples having still an unclear histopathological diagnosis after the second review (n = 67), as well as a random sample of approximately 10% of the first 2000 cancers (n = 182), were blindly re-evaluated by an external expert pathologist for a final evaluation. If there were discrepancies with the local collaborating center, the expert diagnosis prevailed. Pathological classification was based on the World Health Orgnization pathological criteria for HNCs (11) .
HPV-DNA Detection and Genotyping
The detailed methods used for HPV-DNA detection and genotyping have been reported elsewhere in a similar study on cervical cancer specimens (10) . Briefly, we used SPF-10 PCR and a DNA enzyme immunoassay (DEIA) to test for the presence of HPV-DNA. Virus genotyping was performed using reverse hybridization line probe assay (LiPA25_v1) on all samples testing positive for viral DNA, targeting 25 HPV types with different oncogenic potential. Specimens testing positive for HPV-DNA by DEIA, but which could not be typed by LiPA25, were further analyzed by direct Sanger sequencing of PCR products (12) . HPV-DNA-positive cancers that could not be sequenced were labeled "HPV undetermined." DNA quality was evaluated in all HPV-DNA negative samples by testing for the human tubulin gene (13) . All DEIA and LiPA25_v1 assays were performed at ICO. These assays were quality controlled and validated against an external HPV reference lab (DDL Diagnostic Laboratory, Rijswijk, the Netherlands) by cross-testing of 387 anogenital and head and 
HPV E6*I mRNA Detection
All HPV-DNA-positive samples underwent RNA extraction and E6*I mRNA detection at DKFZ, Heidelberg, Germany, as developed by Halec and colleagues (14) . Briefly, the assays target a total of 20 HPV types. For each sample, type-specific E6*I mRNA real-time PCR (RT-PCR) was performed for all available HPV types detected at the DNA level and additionally for HPV16. A random selection (0.6%) of HPV-DNA-negative cancers was tested for HPV16 E6*I mRNA. Detection of housekeeping gene ubiquitin C mRNA was used for RNA quality control in all tested samples.
Immunohistochemistry
Protein expression patterns were evaluated for p16 INK4a , pRb, p53, and Cyclin D1 in all HPV-DNA-positive samples and in a random selection of HPV-DNA-negative cancers in a ratio of 1:1, corresponding approximately to 12% of the negative samples. Stainings were all performed at Hospital General de L'Hospitalet, L'Hospitalet de Llobregat, Spain, under the manufacturer's standards: Roche mtm Laboratories AG (Heidelberg) for p16 INK4a , Vision Biosystems Novocastra (Newcastle) for pRb, and Dako (Denmark) for p53 and Cyclin D1. We used the predefined algorithm developed by Halec and colleagues (15) to determine the cutoff values for over-vs underexpression of each protein. The expected pattern for HPV-driven cancers was overexpression of p16 INK4a and underexpression of the other three markers.
Statistical Analyses
Cancer samples testing negative for both viral and human DNA were excluded from the analyses. HPV-DNA prevalence was calculated as the fraction of HPV-DNA-positive cancers by SPF-10 PCR/DEIA among all samples providing a valid HPV DNA result. In line with work from several authors (15-17), we established that in order to explore algorithms to classify an HNC as HPV-driven we needed to consider markers of HPV infection (HPV-DNA detection), markers of transcriptional activity of HPV oncogenes (HPV E6*I mRNA), and surrogate markers of HPV-related cellular transformation (p16
INK4a
, pRb, p53, and Cyclin D1). We used HPV-DNA and HPV-mRNA positivity as the gold standard to explore the additional value of the other four surrogate markers of cellular transformation by using statistical indicators such as sensitivity, specificity, odds ratios, and area under the receiver operating characteristic (ROC) curves. As shown in Supplementary Table 1 (available online), p16
INK4a expression was the marker that showed the most consistent association with the gold standard across anatomical sites. None of the other markers or combination of markers showed a statistically significant higher area under the ROC curve. Thus, we concluded that using p16
INK4a and/or HPV-mRNA in addition to HPV-DNA yielded the most accurate approximation to judge HPV carcinogenicity in HNCs. Accordingly, we report ranges of markers among all samples validly tested for the corresponding marker or markers, and 95% confidence intervals around point estimates are presented.
We performed sensitivity analyses for p16 INK4a positivity according to three different cutoff points of percentage of stained cells: greater than 25%, greater than 50%, and greater than 75% (Supplementary Table 2 , available online). Because there were no statistically significant differences in the estimates across the three cutoff values, and for consistency sake, we used the greater than 25% cutoff as used by Halec et al. (15) . For the geographical analyses, countries were grouped into world subregions according to the Globocan classification (18) . All statistical tests were two-sided, and statistical significance was set at a P value of less than . Results Figure 1 depicts the disposition of HNC samples collected, processed, and finally tested. The laboratory at ICO received a total of 4533 samples, of which 4022 were tested for HPV-DNA. A total of 3680 HNC samples yielded a valid DNA result and were included in the final analysis: 1264 from the OC, 1374 from the pharynx, and 1042 from the larynx. As compared with other regions, Africa and Asia proportionally contributed more invalid samples (ie, those testing both HPV-DNA-and tubulin-negative) than the other regions: 19.5% and 21.1%, respectively, vs 8.5% in Central-South America and 5% in Europe. Also, samples collected from older periods (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) were more frequently invalid than those collected from more recent periods (2005-2012): 12.6% vs 6.9%, respectively. In contrast, no differences in the percentage of excluded samples were observed by age or sex. Figure 1 also shows the number of HPV-DNA-positive samples that were finally tested for the five additional markers and yielded a valid result. Table 2 shows HPV-DNA prevalence estimates and HPV type-specific distributions by HNC site. Highest HPV prevalence was observed in the oropharynx (24.9%), followed by pharynx unspecified (21.4%), nasopharynx (7.9%), OC (7.4%), larynx (5.7%), and hypopharynx (3.9%). Supplementary Table 3 (available online) presents detailed HPV-DNA data for each anatomic subsite. Among subsites with at least 45 tested samples, cancer of the tonsils showed the highest HPV-DNA prevalence (47%), followed by base of the tongue (18.5%) and oropharynx unspecified (17.9%). HPV16 was by far the most frequently detected genotype among HPV-DNA-positive cancers (75.2%), in particular in the oropharynx (83.0%). Table 2 also presents the results of the HPV-driven expected patterns of the other markers. Among HPV-DNA-positive cancers, underexpression of p53 and HPV E6*I mRNA detection showed the highest prevalence estimates for the three major cancer sites. Among HPV-DNA-negative cancer samples, p16
INK4a overexpression was 13.2%, 10.3%, and 6.4% for OC, oropharynx, and larynx, respectively (data not shown). Corresponding values for underexpression of pRb were 33.7%, 24.9%, and 24.7%; for p53: 59.3%, 48.3%, and 50.6%; and for Cyclin D1: 15.7%, 17.8%, and 23.1%. None of the randomly selected oropharyngeal HPV-DNA-negative samples (n = 20) tested positive for HPV E6*I mRNA (data not shown). Figure 2 presents estimated HPV-AFs using HPV-DNA, HPV E6*I mRNA detection, and overexpression of p16 INK4a . Ranges of AFs when considering HPV-DNA plus E6*I mRNA and/or p16 INK4a were: 18.5% to 22.4% for the oropharynx, 3.0% to 4.4% for the OC, and 1.5% to 3.5% for the larynx. Corresponding values when considering positivity by both HPV-DNA and E6*I mRNA were 21.8%, 3.9%, and 3.1%, respectively. Full results by cancer subsite are provided in Supplementary Table 3 (available online). We observed that within both the oral cavity and the larynx, those subsites that were more proximal to the oropharynx showed higher HPV-AFs than those that were more distal to the oropharynx. Thus, HPV-AFs in combined oral cavity subsites that were proximal to the oropharynx ranged (when considering HPV-DNA plus E6*I mRNA and/or p16 INK4a ) from 4.9% to 6.7%, as opposed 
* NOS = not otherwise specified; SCC = squamous cell carcinoma.
at Universidad de Chile on August 12, 2016 http://jnci.oxfordjournals.org/ Downloaded from Table 2 . HPV-DNA positivity and detected types and E6*I mRNA, p16 || Genotype identified by sequencing. ¶ Multiple infections (n = 7) are not included in these groups. Risk groups are defined according to the last International Agency for Research on Cancer classification: We considered as high-risk HPV types the types included in Group 1, Group 2A, and Group 2B; other HPV types were classified as low-risk HPV types (27) .
# Percentages among HPV-DNA-positive cancers that were tested for each specific marker or combination of markers. Positivity for each individual marker refers to:
detection of E6*I mRNA, overexpression of p16 INK4a , and underexpression of pRb, p53, or Cyclin D1. ** Underexpression.
at Universidad de Chile on August 12, 2016 http://jnci.oxfordjournals.org/ Downloaded from article to 1.4% to 2.3% in subsites that were distal to the oropharynx (P < .001 for both comparisons). Corresponding values in the larynx were 4.2% to 4.2% vs 1.4% to 3.4% in combined subsites that were proximal vs distal to the oropharynx, but these differences were not statistically significant. Table 3 shows prevalence estimates of the key HPV-related markers as well as the final HPV-AF estimates by selected patients' characteristics. Excluding strata with low numbers, HPV-AFs were highest in Central-South America, followed generally by Europe. Globally, women showed higher HPVAFs than men for cancers of the oropharynx and larynx. For oropharyngeal cancer, HPV-AFs were higher in women as compared with men in all European subregions throughout Central-Eastern Europe (61.5% vs 45.5%, P = .09), Southern Europe (22.6% vs 8.4%, P = .002), and Western Europe (38.9% vs 13%, P = .02), but not Northern Europe (50% vs 50%). HPV-AFs were also higher in women as compared with men for cancers of the larynx in South America (23.1% vs 4.2%, P < .001), as well as in Southern Europe (5.9% vs 0.5%, P = .03). In contrast, in the oral cavity we found higher HPV-AFs in men than in women, but only in Northern Europe (10.9% vs 0%, P = .01). We did not identify a clear pattern of sex differences in HPV-AF estimates by calendar period within regions (data not shown). An inverse trend was observed between HPV-AFs and increasing age at diagnosis for each major site. Concerning time trends, HPV-AFs for the oropharynx clearly increased over time: 7.2%, 10.1%, 18.7%, 26.1%, and 32.7% for calendar periods 1990-1994, 1995-1999, 2000-2004, 2005-2009 , and 2010-2012, respectively. In contrast, no trends were observed for the other two major HNC sites.
HPV-AFs showed a marked geographic heterogeneity that was particularly evident for oropharyngeal cancer (Figure 3) . For the oropharynx, AF estimates when considering HPV-DNA plus E6*I mRNA and/or p16 INK4a were highest in South America (48.4%-53.6%), Central-Eastern Europe (44.9%-50%), and Northern Europe (25%-50%), and lowest in Southern Europe (7.6%-9.4%). For the oral cavity, corresponding estimates were highest in South America (5.5%-7.3%), Northern Europe (4.2%-6.8%), and Central America (4.3%); and for the larynx, in South America (3.8%-6.5%), Central America (1.4%-5.6%), and Northern Europe (4.2%). Full results by geographic area are provided in Supplementary Table 4 (available online). Because the study was not powered to calculate precise country-specific estimates, AFs by country are not provided.
Discussion
To our knowledge, this study is the most focused and robust attempt to date to estimate the fraction of HNCs that might be driven by HPV infection. It is now well recognized that article the mere detection of HPV-DNA is not sufficient to establish causality in HNCs. We have thus systematically assessed five additional markers related to HPV biological activity: HPV E6*I mRNA expression and p16, pRb, p53, and Cyclin D1 protein detection. Each of these markers has advantages and limitations (5, 19) . However, one of the key indicators of HPV-related carcinogenicity is HPV E6*I mRNA expression, a marker of transcriptional activity of HPV oncogenes (14, 20) . Consequently, we have used both HPV-DNA and mRNA detection as the gold standard to assess the potential value of adding other surrogate markers of HPV-induced cellular transformation. As shown in Figure 2 , using either or both E6*I mRNA or p16 INK4a in addition to HPV-DNA yielded comparable AFs that were in the range of 18.5% to 22.4% for oropharyngeal cancer, 3.0% to 4.4% for OC cancer, and 1.5% to 3.5% for laryngeal cancer. The percentage point differences between the two methods ranged from 1.4 to 3.9, and they were basically due to lack of expression of p16
INK4a in certain HPV-DNA+/mRNA+ samples. The loss of p16
INK4a in these cancers might be a result of increasing genetic and epigenetic chromosomal instability induced by HPV oncoproteins (20) .
The first observation when assessing these HPV-AFs is the marked heterogeneity across anatomic sites being highest in the oropharynx, substantially lower in the OC, and even lower in the larynx. The probability of an HPV-driven OC cancer was between four and seven times lower than that of oropharyngeal cancer; and that of an HPV-driven laryngeal cancer between five and 15 times lower than that of oropharyngeal cancer. Even within a major site such as the oropharynx, AF estimates ranged from 4.0% in the posterior wall to 45.2% in the tonsil. Being an oropharyngeal subsite, we found an unexpectedly low HPV-AF for cancers of the base of tongue (between 8.7% and 17.4%) but also realized that most of these patients (68/92, 74%) were from Spain, a country known to have low HPV-AFs for HNCs even for the oropharynx (6.7%-8.6%). It is interesting to note that HPVAFs for subsites within the oral cavity that were more proximal to the oropharynx were higher than those that were more distal from the oropharynx. Even though the same was observed for subsites in the larynx, these differences did not reach statistical significance. This gradient of lower HPV involvement in more distant subsites from the oropharynx suggests either misclassification of anatomic subsite or a true biological gradient of HPV involvement.
It is important to note that our estimates of HPV-AFs are substantially lower than those published in the most recent meta-analysis of HPV in HNCs (8): 39.8%, 16.3%, and 8.6% in the oropharynx, OC, and larynx, respectively, when using HPV-mRNA and HPV-DNA positivity. The discrepancy may be because of the very low number of studies reporting on more than one marker and the differences in the geographic origin of the samples, as well as the high heterogeneity in the laboratory procedures and assays used across studies. In contrast, our AF estimates for the oropharynx (18.5%-22.4%) are relatively consistent with another review reporting a population HPV-AF of 25.6% (21) .
We also found important heterogeneity of HPV-AF estimates by geographical region, sex, and age at diagnosis. Estimates ranged from 0% in Africa or Asia to 6.6% in Central-South America for OC, from 18.4% in Asia to 40.5% in Central-South America for the oropharynx, and from 0% in Asia to 6.1% in Central-South America for the larynx. Even within European subregions, wide variations were observed for each cancer site. Even though these estimates may seem low for some regions, it is difficult to make fair comparisons as there are no large studies using several markers of HPV involvement. However, if we use just HPV DNA detection, our estimates are substantially lower than those recently reported, for instance, in a population-based study in the United States, in which HPV-DNA was detected in 70.1% of oropharyngeal, 32.0% of oral cavity, and 20.9% of laryngeal cancers (22) . Concerning sex, HPV-AFs estimates were substantially higher in women than in men, but these differences were only statistically significant in Europe (in all European subregions except Northern Europe) for oropharyngeal cancer and in South America for laryngeal cancer. Finally, we also found that the magnitude of AFs decreased with increasing age for each of the three major HNC sites.
We speculate that globally this large heterogeneity in HPVAFs most likely reflects distinct trends in temporal, geographical, and sociodemographic shifts in population exposure to both tobacco smoking and oral HPV infection, leading to a rapidly evolving epidemiology of HPV-positive HNCs. Indeed, pronounced increasing trends in the incidence of HPV-positive HNCs have been consistently observed in the last decade, in particular for HPV-positive oropharyngeal cancers in young men in Northern Europe and North America (5, (23) (24) (25) (26) at Universidad de Chile on August 12, 2016 http://jnci.oxfordjournals.org/ Downloaded from article prevalent tobacco smoking in the oropharynx between the '60s and early 1980s dominated over those induced by low prevalent oral HPV infections. Since the 1980s, at least in certain populations, the high smoking/HPV prevalence ratios progressively diminished, and while population exposure to tobacco smoking decreased, exposure rates to oral HPV simultaneously increased because of increasing use of oral sex practices. Thus, the current burden of HPV-driven HNCs in a given population may substantially depend on the prevalence and subsequent trends of these exposures starting 15 to 25 years before. Given that our samples were gathered from diverse populations, age groups, and time periods, our estimates might be substantially underestimating the current true burden of HPV-driven HNCs in some geographical areas of the world. In contrast to previous reports, an important new finding of our data is the small HPV-AFs that we found for cancers of the oral cavity (<4.4%) and larynx (<3.5%). These small HPVAFs could well be within the false-positive rate of triple positivity by HPV-DNA, mRNA, and p16. We could also speculate that for these two cancers HPV might be a bystander infection, taking advantage of a tumor that was caused by other means. Therefore, this study cannot rule out a potential effect of false positivity, reverse causation, misclassification of anatomical subsite, or some other artifact of our cross-sectional design and thus conclude that HPV involvement in oral and laryngeal carcinogenesis is probably anecdotal. This could be also the case for the oropharynx, but because the HPV-AFs for this site are higher, the overall impact would be much lower than that in the oral cavity or the larynx.
Despite its strong design and large sample size, our study is not free of limitations. The main one is that while we tested all samples for the presence of HPV-DNA, the five additional markers were assessed in HPV-DNA-positive samples and only in a small fraction of HPV-DNA-negative ones. We therefore cannot completely rule out that we were missing some truly HPVdriven cancers. However, our control testing for HPV16 mRNA among HPV-DNA-negative samples was systematically negative. The effect of this potential misclassification would be towards underestimating the true role of HPV in head and neck carcinogenesis. Lack of representativeness of included samples from a given country or geographic region is also a potential limitation. The small number of samples included from North America and Africa, for instance, limits the validity of our results for these regions. It is clear also that the study is not population based, and as such one cannot exclude some degree of referral or selection bias (ie, centers could serve a biased population in a manner that might be associated with HPV-AFs). The fact that we required participating centers to provide unselected, consecutive HNC samples reduced to a certain degree the potential for selection bias within each center, but not that in the country as a whole. Related to this, it is important to emphasize that overall (ie, worldwide) HPV-AF should not be used nor applied to any one geographic region for the purpose of establishing health policy (for example, cost-effectiveness analysis of vaccination). Region-and cancer site-specific data should be used instead. There has been a problem in misuse of prior data, and having this incorrect use of HPV-AFs may have an erroneous impact.
In conclusion, this study presents robust evidence that the fraction of oropharyngeal cancers that are likely driven by HPV infection, mainly HPV16, is substantial (between 18.5% and 22.4%) but highly heterogeneous with anatomic subsite, geography, and sex. In contrast, the etiological fraction of HPV in cancers of the OC and larynx is substantially lower than previously reported (<4.5%) and also less heterogeneous. Given the rapidly changing epidemiology of HPV-positive HNCs, our estimates might still be underestimating the true impact of HPV in oropharyngeal cancers, and it is likely that in the near future these AFs become even higher. Estimation of the real and evolving contribution of HPV to HNCs is key to forecast the future burden of these cancers as well as to inform on the global potential preventative impact of prophylactic HPV vaccination.
